“…One misconception that sometimes appears in the literature is that the data implicating ion flows, gap junctions, and serotonergic signaling derive solely from drugbased inhibition experiments, and thus are subject to all the usual caveats inherent in pharmacological perturbation. Indeed, chemical genetic strategies (Smukste and Stockwell, 2005;Adams and Levin, 2006a,b;Wheeler and Brandli, 2009) are a rapid and inexpensive method for initially implicating targets for further characterization, as well as allowing dissection of the timing of different mechanisms (which is often impossible with genetic manipulations). However, it is crucial to note that the drug screens that first suggested the involvement of physiological early signals and helped narrow their timing of activity were accompanied by experiments using molecular loss-of-function (and sometimes also gain-of-function) gene-specific reagents Levin and Mercola, 1999;Levin et al, 2002;Bunney et al, 2003;Raya et al, 2004;Fukumoto et al, 2005a,b;Adams et al, 2006;Morokuma et al, 2008) in every major study, rendering concerns about pharmacological specificity irrelevant and firmly implicating several ion transport and neurotransmitter pathways in LR patterning.…”